Casitas B lineage lymphoma b Is a key regulator of peripheral tolerance in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 65, Issue 4, 2013, Pages 1032-1042

  Gõmez Martín, Diana ^a   Ibarra Sánchez, María ^a   Romo Tena, Jorge ^a   Cruz Ruíz, José ^a   Esparza Lõpez, José ^a   Galindo Campos, Miguel ^a   Díaz Zamudio, Mariana ^a   Alcocer Varela, Jorge ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CASITAS B LINEAGE LYMPHOMA B; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 2; IONOMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECEPTOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CD4+ T LYMPHOCYTE; CELL LINEAGE; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DILUTION; FEMALE; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS RASH; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CLONAL ANERGY; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PERIPHERAL TOLERANCE; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84875708892     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37833     Document Type: Article

References (48)

1. Liu YC, Penninger J, Karin M,. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol 2005; 5: 941-52.
2. + T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem 2007; 282: 9696-702.
3. Heissmeyer V, Macian F, Im SH, Varma R, Feske S, Venuprasad K, et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 2004; 5: 255-65.
4. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A,. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002; 109: 719-31.
5. Liu YC,. Ubiquitin ligases and the immune response. Annu Rev Immunol 2004; 22: 81-127.
6. Jeon MS, Atfield A, Venuprasad K, Krawczyk C, Sarao R, Elly C, et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004; 21: 167-77.
7. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000; 403: 216-20.
8. Fang D, Liu YC,. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2001; 2: 870-5.
9. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000; 403: 211-6.
10. + T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J Exp Med 2001; 193: 329-37.
11. Crispin JC, Kyttaris VC, Juang YT, Tsokos GC,. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 2008; 29: 110-5.
12. Schwartz RH,. T cell anergy. Annu Rev Immunol 2003; 21: 305-34.
13. Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC,. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 2001; 166: 4216-22.
14. + T cells from lupus-prone mice avoid antigen-specific tolerance induction in vivo. J Immunol 2003; 170: 741-8.
15. Yi Y, McNerney M, Datta SK,. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000; 165: 6627-34.
16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
17. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
18. Parish CR, Glidden MH, Quah BJ, Warren HS,. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr Protoc Immunol 2009;Chapter 4:Unit4.9.
19. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J,. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008; 17: 289-94.
20. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2 -ΔΔC T method. Methods 2001; 25: 402-8.
21. Ettenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, Pierce JH, et al. Cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 1999; 18: 1855-66.
22. Alcocer-Varela J, Alarcon-Segovia D,. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69: 1388-92.
23. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA,. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130: 2651-5.
24. Naides SJ,. Suppression of antigen-specific interleukin 2 production in the MRL/MpJ-lpr/lpr mouse. J Immunol 1986; 136: 4113-21.
25. Lin JT, Lineberry NB, Kattah MG, Su LL, Utz PJ, Fathman CG, et al. Naive CD4 T cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression. J Immunol 2009; 182: 5919-28.
26. Fritsch RD, Shen X, Illei GG, Yarboro CH, Prussin C, Hathcock KS, et al. Abnormal differentiation of memory T cells in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2184-97.
27. + T cells induced by low avidity engagement of T cell receptor. J Exp Med 2001; 194: 719-31.
28. Chen D, Heath V, O'Garra A, Johnston J, McMahon M,. Sustained activation of the raf-MEK-ERK pathway elicits cytokine unresponsiveness in T cells. J Immunol 1999; 163: 5796-805.
29. Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L,. Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol Pharm Bull 2010; 33: 40-6.
30. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM,. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science 1997; 278: 124-8.
31. Quill H, Riley MP, Cho EA, Casnellie JE, Reed JC, Torigoe T,. Anergic Th1 cells express altered levels of the protein tyrosine kinases p56lck and p59fyn. J Immunol 1992; 149: 2887-93.
32. Murakawa Y, Sakane T,. Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum 1988; 31: 826-33.
33. Dure M, Macian F,. IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes. Mol Immunol 2009; 46: 999-1006.
34. Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, et al. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 2005; 174: 5630-5.
35. -/- mice. J Immunol 2004; 173: 1059-65.
36. Villarino AV, Katzman SD, Gallo E, Miller O, Jiang S, McManus MT, et al. Posttranscriptional silencing of effector cytokine mRNA underlies the anergic phenotype of self-reactive T cells. Immunity 2011; 34: 50-60.
37. + T cell clonal expansion. J Immunol 2008; 181: 5331-9.
38. Su LL, Iwai H, Lin JT, Fathman CG,. The transmembrane E3 ligase GRAIL ubiquitinates and degrades CD83 on CD4 T cells. J Immunol 2009; 183: 438-44.
39. Lineberry NB, Su LL, Lin JT, Coffey GP, Seroogy CM, Fathman CG,. The transmembrane E3 ligase GRAIL ubiquitinates the costimulatory molecule CD40 ligand during the induction of T cell anergy. J Immunol 2008; 181: 1622-6.
40. Doniz-Padilla L, Martinez-Jimenez V, Nino-Moreno P, Abud-Mendoza C, Hernandez-Castro B, Gonzalez-Amaro R, et al. Expression and function of Cbl-b in T cells from patients with systemic lupus erythematosus, and detection of the 2126 A/G Cblb gene polymorphism in the Mexican mestizo population. Lupus 2011; 20: 628-35.
41. Schwartz RH,. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996; 184: 1-8.
42. + T cells by alternatively activated dendritic cells. J Leukoc Biol 2008; 84: 124-33.
43. 2-terminal kinase and mitogen-activated protein kinase signaling pathways. J Exp Med 1996; 183: 2017-23.
44. + T cells. Science 1996; 271: 1272-6.
45. Migita K, Eguchi K, Kawabe Y, Tsukada T, Ichinose Y, Nagataki S, et al. Defective TCR-mediated signaling in anergic T cells. J Immunol 1995; 155: 5083-7.
46. Adler HS, Steinbrink K,. MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle 2008; 7: 169-70.
47. Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, Blazar BR, et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 2000; 6: 290-7.
48. Li L, Iwamoto Y, Berezovskaya A, Boussiotis VA,. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol 2006; 7: 1157-65.